3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
11
Polycystic Ovary Syndrome
4
Prostatic Neoplasms
2
Heart Failure
2
Cardiotoxicity
2
Solid Tumors
1
Pediatric Brain Tumor
1
Pancreatic Neoplasms
1
Obesity
1
Lung Neoplasms
1
Inflammation
1
Hyperinsulinism
1
Hyperglycemia
1
Hereditary Sensory and Autonomic Neuropathies
1
Diabetes Mellitus, Type 2
1
Diabetes Mellitus
1
Adenocarcinoma of Lung
1
Interventions
Insulin Glargine
4
Insulin
3
volagidemab
2
Metformin
2
Fulvestrant
2
Alpelisib
2
ziprasidone
1
relacorilant
1
pembrolizumab
1
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Olanzapine
1
Letrozole
1
Insulin Lispro
1
Insulin Aspart
1
Injections
1
DNA, Ribosomal
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hyperglycemia
×
dapagliflozin
×
Clear all
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts